Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

NCT01703949 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Hodgkin Lymphoma
Recurrent Non-Hodgkin Lymphoma
Refractory Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab

Sponsor

University of Washington